Literature DB >> 363967

Effects in animals of chronic administration of spironolactone--a review.

G Lumb, P Newberne, J H Rust, B Wagner.   

Abstract

Spironolactone, an aldosterone antagonist, has been found effective in the treatment of certain forms of hypertension, ascites, and edematous conditions. Since patients may receive daily doses of spironolactone for many years, it is important to determine the chronic effects on tissues. This study reviews the tissue changes in rats, dogs, and monkeys receiving spironolactone daily for up to two years. Dose levels were frequently in excess of 100 times the recommended human dose. The pituitary, adrenals, and kidneys of all animals showed no significant changes. Histologic changes were noted in rat livers, thyroid, and male internal genitalia. There were alterations in monkey testes and male mammary glands. This study found no evidence to suggest that spironolactone is tumorigenic or carcinogenic. Species differences in metabolism may account for the diversity of tissue observations.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 363967

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol        ISSN: 0146-4779


  5 in total

1.  Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response.

Authors:  Ayala Gold; Lital Eini; Malka Nissim-Rafinia; Ruth Viner; Shlomit Ezer; Keren Erez; Nasma Aqaqe; Rotem Hanania; Michael Milyavsky; Eran Meshorer; Michal Goldberg
Journal:  Oncogene       Date:  2019-01-08       Impact factor: 9.867

Review 2.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

3.  Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Authors:  C S Cook; C L Hauswald; G L Schoenhard; C E Piper; A Patel; F M Radzialowski; J D Hribar; W Aksamit; P Finnegan; R H Bible
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

4.  Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia.

Authors:  M Fischer; W Vetter; B Winterg; W Zidek; H Vetter
Journal:  Eur J Nucl Med       Date:  1982

Review 5.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.

Authors:  Peter Kolkhof; Lars Bärfacker
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.